Robert Ennis, MD
Endocrinology, Diabetes & Metabolism · Meridian, IDNPI 1366647729
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,425 of the $68,543 with a category attached, or 73.6%. Lilly USA, LLC accounts for 92.8% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $62,722 and has fallen 99.5% since, to $301 in 2025.
Across 484 payments — averaging $141.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$64K
- Novo Nordisk$1K
- Amgen$674
- Corcept Therapeutics$453
- Antares Pharma, Inc.$413
- Dexcom, Inc.$338
- plus $2K from 30 others
What the payments were for
- Consulting fees$5,8509%
- Speaking & faculty fees$50,42574%
- Travel & lodging$5,0187%
- Food & beverage$7,16810%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 156 | $63,636 |
| Novo Nordisk | 125 | $1,105 |
| Amgen(2 entities) | 24 | $674 |
| Corcept Therapeutics | 24 | $453 |
| Antares Pharma, Inc. | 47 | $413 |
| Dexcom, Inc. | 11 | $338 |
| AstraZeneca(2 entities) | 17 | $322 |
| Abbott | 8 | $240 |
| Sanofi-aventis U.S. LLC | 12 | $205 |
| Amarin Pharma, Inc. | 4 | $163 |
| Insulet Corporation | 8 | $150 |
| Radius Health, Inc. | 7 | $122 |
| Tandem Diabetes Care, Inc. | 5 | $94 |
| Medtronic(2 entities) | 4 | $68 |
| Merck | 4 | $62 |
| Novartis | 3 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $47 |
| Senseonics, Incorporated | 1 | $41 |
| Recordati_rare_diseases_inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $26 |
| Johnson & Johnson | 2 | $25 |
| Companion Medical, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Exact Sciences | 1 | $17 |
| AbbVie | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| EUSA Pharma (US) LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Mayne Pharma Commercial LLC | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 117 | $143,285 |
| OzempicSemaglutide | 84 | $138,203 |
| JardianceEmpagliflozin | 104 | $123,878 |
| FarxigaDapagliflozin Propanediol | 89 | $105,042 |
| MounjaroTirzepatide | 53 | $78,575 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $60,153 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $41,627 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $36,140 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $31,863 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $28,885 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $26,779 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $23,648 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $13,825 |
| NovologInsulin Aspart | 39 | $12,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $11,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $63,636 | $231,702204 claims |
| Boehringer IngelheimJardiance, Glyxambi | $26 | $155,740125 claims |
| Novo NordiskOzempic, Novolog | $1,105 | $150,291123 claims |
| AstraZenecaFarxiga | $322 | $105,04289 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $205 | $36,14020 claims |
| AbbVieSynthroid, Armour Thyroid | $17 | $11,360138 claims |
| Johnson & JohnsonInvokana | $25 | $6,84212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Meridian
- Michael HolyoakMeridian$2K
- Johannes VeldhuisMeridian$80
- Lynn Ge-ZerbeMeridian$0
- Theodore RooseveltBoise$65K
- David LiljenquistIdaho Falls$9K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.